JorgeEnriqueMachado-‐Alba
90
94. Nahta R. Molecular Mechanisms of Trastuzumab-‐Based Treatment in HER2-‐
OverexpressingBreast Cancer. ISRNOncol
2012
, 428062(2012).
95. GunturuKS,WooY, BeaubierN, RemottiHE, SaifMW. Gastric cancer and trastuzumab: first
biologic therapy ingastric cancer. TherAdvMedOncol
5
(2), 143-‐51(2013).
96. Qin T, Yuan Z, Peng R, Bai B, Shi Y, Teng X, et al. HER2-‐positive breast cancer patients
receiving trastuzumab treatment obtainprognosis comparablewith that ofHER2-‐negative
breast cancerpatients. OncoTargetsTher
6
, 341-‐7(2013).
97. Stebbing J, Payne R, Reise J, Frampton AE, Avery M, et al. The Efficacy of Lapatinib in
Metastatic Breast Cancer with HER2 Non-‐Amplified Primary Tumors and EGFR Positive
CirculatingTumorCells: AProof-‐Of-‐Concept Study. PLoSONE
8
(5), e62543(2013).
98. Diessner J, Bruttel V, Becker K, PawlikM, Stein R, Häusler S, et al. Targeting breast cancer
stem cells with HER2-‐specific antibodies and natural killer cells. Am J Cancer Res
3
(2),
211-‐20(2013).
99. Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ. Treating breast cancer in the 21st
century: emergingbiological therapies. J Cancer
4
(2), 117-‐32(2013).
100. Chen F-‐T, Yang C-‐M, Yang C-‐H. The Protective Effects of the Proteasome Inhibitor
Bortezomib (Velcade) on Ischemia-‐Reperfusion Injury in the Rat Retina. PLoS ONE
8
(5),
e64262(2013).
101. Vacchelli E, Eggermont A, Galon J, Sautès-‐Fridman C, Zitvogel L, Kroemer G, et al. Trial
watch:Monoclonal antibodies incancer therapy. Oncoimmunology
2
(1), e22789(2013).
102. Machado J, Moncada JC, Pineda R. [Profile of use of anti tumor necrosis factor in
Colombianpatients]. Biomedica
31
(2), 250-‐7(2011).
103. Machado Alba JE, Moncada Escobar JC. [Evolution of consumption of high-‐cost drugs in
Colombia]. RevPanamSaludPublica
31
(4), 283-‐9(2012).
